Search

Your search keyword '"Andreu, José Luis"' showing total 231 results
Start Over Author "Andreu, José Luis"
231 results on '"Andreu, José Luis"'

1. The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation

Author

Gordon, Rachael A., Nguyen, Yann, Foulquier, Nathan, Beydon, Maxime, Gheita, Tamer A, Hajji, Raouf, Sahbudin, Ilfita, Hoi, Alberta, Ng, Wan-Fai, Mendonça, Jose Alexandre, Wallace, Daniel J, Shea, Beverley, Bruyn, George AW, Goodman, Susan M, Fisher, Benjamin A, Baldini, Chiara, Torralba, Karina D, Bootsma, Hendrika, Akpek, Esen K, Karakus, Sezen, Baer, Alan N, Chakravarty, Soumya D, Terslev, Lene, D'Agostino, Maria-Antonietta, Mariette, Xavier, DiRenzo, Dana, Rasmussen, Astrid, Papas, Athena, Montoya, Cristina, Arends, Suzanne, Yusof, Md Yuzaiful Md, Pintilie, Ionut, Warner, Blake M., Hammitt, Katherine M., Strand, Vibeke, Bouillot, Coralie, Tugwell, Peter, Inanc, Nevsun, Andreu, José Luis, Wahren-Herlenius, Marie, Devauchelle-Pensec, Valerie, Shiboski, Caroline H., Benyoussef, Anas, Masli, Sharmila, Lee, Adrian Y.S., Cornec, Divi, Bowman, Simon, Rischmueller, Maureen, McCoy, Sara S, and Seror, Raphaele

Published
2024
Full Text
View/download PDF

2. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

Author

Laíño-Piñeiro, María-Cruz, Rúa-Figueroa, Iñigo, Jiménez, Norman, Lozano, María José Cuadrado, Martínez-Barrio, Julia, Serrano, Belén, Galindo-Izquierdo, María, Nack, Annika, Loricera, Javier, Tomero-Muriel, Eva, Ibáñez-Barceló, Mónica, Vázquez, Natalia Mena, Manrique-Arija, Sara, Lorenzo, Nerea Alcorta, Narváez, Javier, Rosas, José, Menor-Almagro, Raúl, Martínez-Taboada, Víctor Manuel, Aurrecoechea-Aguinaga, Elena, Horcada, Loreto, Ruiz-Lucea, Esther, Raya, Enrique, Toyos, F Javier, Expósito, Lorena, Vela, Paloma, Freire-González, Mercedes, Moriano-Morales, Clara, Bonilla-Hernán, Gema, Ibáñez, Tatiana Cobo, Lozano-Rivas, Nuria, Moreno, Mireia, Andreu, José Luis, Ubiaga, Carlota Laura Iniguez, Torrente-Segarra, Vicenç, Valls, Elia, Velloso-Feijoo, M.L., Alcázar, Juan Luis, and Pego-Reigosa, José M

Published
2023
Full Text
View/download PDF

10. Evaluación protocolizada odontológica en el paciente con síndrome de Sjögren primario. Proyecto EPOX-SSp: metodología y objetivos

Author

Hernández Vallejo, Gonzalo, Ángeles Blázquez, M., Bohórquez, Cristina, Bonilla, Gema, Cobo, Tatiana, García Vadillo, Jesús, González Martín, Jorge Juan, Illera, Oscar, Lojo, Leticia, López Longo, Francisco Javier, Melchor, Sheila, Teresa Navío, María, Nuño, Laura, Carmen Ortega, María, Peiteado, Diana, Recuerdo, Sheila, Richi, Patricia, Rodríguez, Ana, Steiner, Martina, Valero, Marta, Fernández Castro, Mónica, López-Pintor, Rosa María, Serrano, Julia, Ramírez, Lucía, Sanz, Mariano, Andreu, Jose Luis, and Muñoz Fernández, Santiago

Published
2021
Full Text
View/download PDF

11. The Sjögren's Working Group:The 2023 OMERACT meeting and provisional domain generation

Author

Gordon, Rachael A., Nguyen, Yann, Foulquier, Nathan, Beydon, Maxime, Gheita, Tamer A., Hajji, Raouf, Sahbudin, Ilfita, Hoi, Alberta, Ng, Wan Fai, Mendonça, Jose Alexandre, Wallace, Daniel J., Shea, Beverley, Bruyn, George AW, Goodman, Susan M., Fisher, Benjamin A., Baldini, Chiara, Torralba, Karina D., Bootsma, Hendrika, Akpek, Esen K., Karakus, Sezen, Baer, Alan N., Chakravarty, Soumya D., Terslev, Lene, D'Agostino, Maria Antonietta, Mariette, Xavier, DiRenzo, Dana, Rasmussen, Astrid, Papas, Athena, Montoya, Cristina, Arends, Suzanne, Yusof, Md Yuzaiful Md, Pintilie, Ionut, Warner, Blake M., Hammitt, Katherine M., Strand, Vibeke, Bouillot, Coralie, Tugwell, Peter, Inanc, Nevsun, Andreu, José Luis, Wahren-Herlenius, Marie, Devauchelle-Pensec, Valerie, Shiboski, Caroline H., Benyoussef, Anas, Masli, Sharmila, Lee, Adrian Y.S., Cornec, Divi, Bowman, Simon, Rischmueller, Maureen, McCoy, Sara S., Seror, Raphaele, Gordon, Rachael A., Nguyen, Yann, Foulquier, Nathan, Beydon, Maxime, Gheita, Tamer A., Hajji, Raouf, Sahbudin, Ilfita, Hoi, Alberta, Ng, Wan Fai, Mendonça, Jose Alexandre, Wallace, Daniel J., Shea, Beverley, Bruyn, George AW, Goodman, Susan M., Fisher, Benjamin A., Baldini, Chiara, Torralba, Karina D., Bootsma, Hendrika, Akpek, Esen K., Karakus, Sezen, Baer, Alan N., Chakravarty, Soumya D., Terslev, Lene, D'Agostino, Maria Antonietta, Mariette, Xavier, DiRenzo, Dana, Rasmussen, Astrid, Papas, Athena, Montoya, Cristina, Arends, Suzanne, Yusof, Md Yuzaiful Md, Pintilie, Ionut, Warner, Blake M., Hammitt, Katherine M., Strand, Vibeke, Bouillot, Coralie, Tugwell, Peter, Inanc, Nevsun, Andreu, José Luis, Wahren-Herlenius, Marie, Devauchelle-Pensec, Valerie, Shiboski, Caroline H., Benyoussef, Anas, Masli, Sharmila, Lee, Adrian Y.S., Cornec, Divi, Bowman, Simon, Rischmueller, Maureen, McCoy, Sara S., and Seror, Raphaele

Abstract

Sjögren's disease (SjD) is a systemic autoimmune exocrinopathy with key features of dryness, pain, and fatigue. SjD can affect any organ system with a variety of presentations across individuals. This heterogeneity is one of the major barriers for developing effective disease modifying treatments. Defining core disease domains comprising both specific clinical features and incorporating the patient experience is a critical first step to define this complex disease. The OMERACT SjD Working Group held its first international collaborative hybrid meeting in 2023, applying the OMERACT 2.2 filter toward identification of core domains. We accomplished our first goal, a scoping literature review that was presented at the Special Interest Group held in May 2023. Building on the domains identified in the scoping review, we uniquely deployed multidisciplinary experts as part of our collaborative team to generate a provisional domain list that captures SjD heterogeneity, Sjögren's disease (SjD) is a systemic autoimmune exocrinopathy with key features of dryness, pain, and fatigue. SjD can affect any organ system with a variety of presentations across individuals. This heterogeneity is one of the major barriers for developing effective disease modifying treatments. Defining core disease domains comprising both specific clinical features and incorporating the patient experience is a critical first step to define this complex disease. The OMERACT SjD Working Group held its first international collaborative hybrid meeting in 2023, applying the OMERACT 2.2 filter toward identification of core domains. We accomplished our first goal, a scoping literature review that was presented at the Special Interest Group held in May 2023. Building on the domains identified in the scoping review, we uniquely deployed multidisciplinary experts as part of our collaborative team to generate a provisional domain list that captures SjD heterogeneity.

Published
2024

14. Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature

Author

Silva-Fernández, Lucía, Otón, Teresa, Askanase, Anca, Carreira, Patricia, López-Longo, Francisco Javier, Olivé, Alejandro, Rúa-Figueroa, Íñigo, Narváez, Javier, Ruiz-Lucea, Esther, Andrés, Mariano, Calvo, Enrique, Toyos, Francisco, Alegre-Sancho, Juan José, Tomero, Eva, Montilla, Carlos, Zea, Antonio, Uriarte, Esther, Calvo-Alén, Jaime, Marras, Carlos, Martínez-Taboada, Víctor M., Belmonte-López, María Ángeles, Rosas, José, Raya, Enrique, Bonilla, Gema, Freire, Mercedes, Pego-Reigosa, José María, Millán, Isabel, Hughes-Morley, Adwoa, and Andreu, José Luis

Published
2019
Full Text
View/download PDF

17. Recommendations for the Use of Ultrasound and Magnetic Resonance in Patients With Rheumatoid Arthritis

Author

Möller, Ingrid, Loza, Estibaliz, Uson, Jacqueline, Acebes, Carlos, Andreu, Jose Luis, Batlle, Enrique, Bueno, Ángel, Collado, Paz, Fernández-Gallardo, Juan Manuel, González, Carlos, Jiménez Palop, Mercedes, Lisbona, María Pilar, Macarrón, Pilar, Maymó, Joan, Narváez, Jose Antonio, Navarro-Compán, Victoria, Sanz, Jesús, Rosario, M. Piedad, Vicente, Esther, and Naredo, Esperanza

Published
2018
Full Text
View/download PDF

18. Recommendations for the Use of Ultrasound and Magnetic Resonance in Patients With Spondyloarthritis, Including Psoriatic Arthritis, and Patients With Juvenile Idiopathic Arthritis

Author

Uson, Jacqueline, Loza, Estibaliz, Möller, Ingrid, Acebes, Carlos, Andreu, Jose Luis, Batlle, Enrique, Bueno, Ángel, Collado, Paz, Fernández-Gallardo, Juan Manuel, González, Carlos, Jiménez Palop, Mercedes, Lisbona, María Pilar, Macarrón, Pilar, Maymó, Joan, Narváez, Jose Antonio, Navarro-Compán, Victoria, Sanz, Jesús, Rosario, M. Piedad, Vicente, Esther, and Naredo, Esperanza

Published
2018
Full Text
View/download PDF

19. Recomendaciones para el uso de la ecografía y la resonancia magnética en pacientes con artritis reumatoide

Author

Möller, Ingrid, Loza, Estibaliz, Uson, Jacqueline, Acebes, Carlos, Andreu, Jose Luis, Batlle, Enrique, Bueno, Ángel, Collado, Paz, Fernández-Gallardo, Juan Manuel, González, Carlos, Jiménez Palop, Mercedes, Lisbona, María Pilar, Macarrón, Pilar, Maymó, Joan, Narváez, Jose Antonio, Navarro-Compán, Victoria, Sanz, Jesús, Rosario, M. Piedad, Vicente, Esther, and Naredo, Esperanza

Published
2018
Full Text
View/download PDF

20. Recomendaciones para el uso de la ecografía y la resonancia magnética en pacientes con espondiloartritis, incluyendo la artritis psoriásica, y en pacientes con artritis idiopática juvenil

Author

Uson, Jacqueline, Loza, Estibaliz, Möller, Ingrid, Acebes, Carlos, Andreu, Jose Luis, Batlle, Enrique, Bueno, Ángel, Collado, Paz, Fernández-Gallardo, Juan Manuel, González, Carlos, Jiménez Palop, Mercedes, Lisbona, María Pilar, Macarrón, Pilar, Maymó, Joan, Narváez, Jose Antonio, Navarro-Compán, Victoria, Sanz, Jesús, Rosario, M. Piedad, Vicente, Esther, and Naredo, Esperanza

Published
2018
Full Text
View/download PDF

25. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort

Author

Narváez, Javier, Borrell, Helena, Sánchez-Alonso, Fernando, Rúa-Figueroa, Iñigo, López-Longo, Francisco Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Fernández-Nebro, Antonio, Olivé, Alejandro, Andreu, José Luis, Martínez-Taboada, Víctor, Nolla, Joan Miquel, Pego-Reigosa, José María, and on behalf of the RELESSER Study Group

Published
2018
Full Text
View/download PDF

26. 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis

Author

Sanmartí, Raimon, García-Rodríguez, Susana, Álvaro-Gracia, José María, Andreu, José Luis, Balsa, Alejandro, Cáliz, Rafael, Fernández-Nebro, Antonio, Ferraz-Amaro, Iván, Gómez-Reino, Juan Jesús, González-Álvaro, Isidoro, Martín-Mola, Emilio, Martínez-Taboada, Víctor Manuel, Ortiz, Ana M., Tornero, Jesús, Marsal, Sara, and Moreno-Muelas, José Vicente

Published
2015
Full Text
View/download PDF

28. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

Author

Sanmartí, Raimon, García-Rodríguez, Susana, Álvaro-Gracia, José María, Andreu, José Luis, Balsa, Alejandro, Cáliz, Rafael, Fernández-Nebro, Antonio, Ferraz-Amaro, Iván, Gómez-Reino, Juan Jesús, González-Álvaro, Isidoro, Martín-Mola, Emilio, Martínez-Taboada, Víctor Manuel, Ortiz, Ana M., Tornero, Jesús, Marsal, Sara, and Moreno-Muelas, José Vicente

Published
2015
Full Text
View/download PDF

39. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)

Author

Torrente-Segarra, Vicenç, Salman-Monte, Tarek C, Rúa-Figueroa, Íñigo, Del Campo, Víctor, López-Longo, Francisco Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Olivé-Marqués, Alejandro, Mouriño-Rodríguez, Coral, Horcada, Loreto, Bohórquez, Cristina, Montilla, Carlos, Salgado, Eva, Díez-Álvarez, Elvira, Blanco, Ricardo, Andreu, José Luis, Fernández-Berrizbeitia, Olaia, Expósito, Lorena, Gantes, Marian, Hernández-Cruz, Blanca, Pecondón-Español, Ángela, Lozano-Rivas, Nuria, Bonilla, Gema, Lois Iglesias, Ana, Rubio-Muñoz, Paula, Ovalles, Juan, Tomero, Eva, Boteanu, Alina, Narvaez, Javier, Freire, Mercedes, Vela, Paloma, Quevedo-Vila, Víctor, Juan Mas, Antonio, Muñoz-Fernández, Santiago, Raya, Enrique, Moreno, Mireia, Velloso-Feijoo, M L, Soler, Gregorio, Vázquez-Rodríguez, Tomás Ramón, Pego-Reigosa, José M, and RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER)

Subjects
Adult, Male, RELESSER, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Splenectomy, Serious infection, Infections, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Adrenal Cortex Hormones, Internal medicine, medicine, Humans, Lupus Erythematosus, Systemic, Registries, 030212 general & internal medicine, Serious Infections, Child, skin and connective tissue diseases, Retrospective Studies, 030203 arthritis & rheumatology, Juvenile-onset Systemic Lupus Erythematosus, Systemic lupus erythematosus, business.industry, Incidence, Incidence (epidemiology), Retrospective cohort study, medicine.disease, 3. Good health, Large cohort, Cross-Sectional Studies, Anesthesiology and Pain Medicine, Juvenile onset, Female, business, Immunosuppressive Agents, Follow-Up Studies
Abstract

Objective: To assess the incidence of serious infection (SI) and associated factors in a large juvenile-onset systemic lupus erythematosus (jSLE) retrospective cohort. Methods: All patients in the Spanish Rheumatology Society Lupus Registry (RELESSER) who meet >= 4 ACR-97 SLE criteria and disease onset = 6, 5.8%). Incidence rate was 3.7 (95%CI: 3.2-4.2) SI per 100 patient years. Respiratory location and bacterial infections were the most frequent. Higher number of SLE classification criteria, SLICC/ACR DI score and immunosuppressants use were associated to the presence of SI. Associated factors to shorter time to first infection were higher number of SLE criteria, splenectomy and immunosuppressants use. Conclusions: The risk of SI in jSLE patients is significant and higher than aSLE. It is associated to higher number of SLE criteria, damage accrual, some immunosuppressants and splenectomy. (C) 2020 Elsevier Inc. All rights reserved.

Published
2020

40. Benign rheumatoid nodule in the soleus muscle. Case report

Author

Rusinovich, Olga, Morán, Luz María, Nájera Botello, Laura, and Andreu, José Luis

Subjects
Nódulo reumatoide benigno, Diagnóstico diferencial nódulo reumatoide, Clinical manifestations of rheumatoid nodule, Rheumatoid nodule, Nódulo reumatoide, Manifestaciones clínicas nódulo reumatoide, Tratamiento nódulo, Benign rheumatoid nodule, Differential diagnosis of rheumatoid nodule, Treatment of rheumatoid nodule
Abstract

RESUMEN Los nódulos reumatoides benignos son nódulos subcutáneos, idénticos en su morfología e histología a los que ocurren en el transcurso de la artritis reumatoide (AR), que aparecen en personas sin síntomas de artritis y con factor reumatoide (FR) negativo. Se presenta el caso de un varón de 46 arios de raza caucasiana que consultó por tumoración en la pierna derecha. Destacaba negatividad de factor reumatoide, anticuerpos anti péptido citrulinado, anticuerpos antinucleares y anticuerpos anticitoplasma de neutrófilo, así como normalidad de los reactantes de fase aguda. Una ecografía musculoesquelética mostró una tumoración sólida de 3,5 x 1,5 cm, de márgenes bien definidos, en músculo sóleo, con una estructura heterogénea hipoecoica con vascularización intra y perilesional. La resonancia magnética evidenció una tumoración de carácter fibroso sin datos sugestivos de agresividad. Una biopsia guiada por ecografía mostró histología característica de nódulo reumatoide. Se discuten la clínica, el diagnóstico, el diagnóstico diferencial y el tratamiento de los nódulos reumatoides benignos. ABSTRACT Benign rheumatoid nodules are subcutaneous nodules, identical in morphology and histo logy to those that occur in the course of rheumatoid arthritis. They appear in people without symptoms of arthritis and with negative rheumatoid factor. The case is presented of a 46-year-old Caucasian man who consulted for a tumour inthe right leg. He was negative for rheumatoid factor, anti-citrullinated protein antibodies, antinuclear antibodies, and antineutrophil cytoplasmic antibodies, as well as for acute phase reactants. A musculoskeletal ultrasound showed a solid tumour of 3.5 × 1.5 cm with well-defined margins in the soleus muscle, and with a heterogeneous hypoechoic structure with intra- and peri-lesional vascularisation. The magnetic resonance imaging showed a fibrous tumour with no signs suggestive of aggressive growth. An ultrasound-guided biopsy sho wed the characteristic histology of the rheumatoid nodule. The clinical picture, diagnosis, differential diagnosis, and treatment of benign rheumatoid nodules are discussed.

Published
2022

41. Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients

Author

Gómez Reino, Juan, Loza, Estíbaliz, Andreu, José Luis, Balsa, Alejandro, Batlle, Enrique, Cañete, Juan D., Collantes Estévez, Eduardo, Fernández Carballido, Cristina, Fernández Sueiro, José Luis, García de Vicuña, Rosario, González-Álvaro, Isidoro, González Fernández, Carlos, Juanola, Xavier, Linares, Luis Francisco, Marenco, José Luis, Martín Mola, Emilio, Moreno Ramos, Manuel, Mulero Mendoza, Juan, Muñoz Fernández, Santiago, Queiro, Rubén, Richi Alberti, Patricia, Sanz, Jesús, Tornero Molina, Jesús, Zarco Montejo, Pedro, and Carmona, Loreto

Published
2011
Full Text
View/download PDF

43. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

Author

Reino, Juan Gómez, Loza, Estíbaliz, Andreu, José Luis, Balsa, Alejandro, Batlle, Enrique, Cañete, Juan D., Collantes Estévez, Eduardo, Fernández Carballido, Cristina, Fernández Sueiro, José Luis, García de Vicuña, Rosario, González-Álvaro, Isidoro, González Fernández, Carlos, Juanola, Xavier, Linares, Luis Francisco, Marenco, José Luis, Martín Mola, Emilio, Moreno Ramos, Manuel, Mulero Mendoza, Juan, Muñoz Fernández, Santiago, Queiro, Rubén, Richi Alberti, Patricia, Sanz, Jesús, Tornero Molina, Jesús, Zarco Montejo, Pedro, and Carmona, Loreto

Published
2011
Full Text
View/download PDF

47. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review.

Author

Herrero-Morant, Alba, Martín-Varillas, José Luis, Castañeda, Santos, Maíz, Olga, Sánchez, Julio, Ortego, Norberto, Raya, Enrique, Prior-Español, Águeda, Moriano, Clara, Melero-González, Rafael B, Graña-Gil, Jenaro, Urruticoechea-Arana, Ana, Ramos-Calvo, Ángel, Loredo-Martínez, Marta, Salgado-Pérez, Eva, Sivera, Francisca, Torre, Ignacio, Narváez, Javier, Andreu, José Luis, and Martínez-González, Olga

Subjects
THERAPEUTIC use of monoclonal antibodies, DRUG efficacy, RESEARCH, C-reactive protein, CLINICAL trials, BEHCET'S disease, ANTI-inflammatory agents, TOCILIZUMAB, MONOCLONAL antibodies, DRUG resistance, INFLIXIMAB, NEUROLOGIC manifestations of general diseases, BLOOD sedimentation, DESCRIPTIVE statistics, ADALIMUMAB, PREDNISONE, LONGITUDINAL method, DISEASE remission, GOLIMUMAB, ETANERCEPT, EVALUATION
Abstract

Objectives To assess efficacy and safety of biologic therapy (BT) in neurobehçet's disease (NBD) refractory to glucocorticoids and at least one conventional immunosuppressive drug. Methods Open-label, national, multicentre study. NBD diagnosis was based on the International Consensus Recommendation criteria. Outcome variables were efficacy and safety. Main efficacy outcome was clinical remission. Other outcome variables analysed were glucocorticoid-sparing effect and improvement in laboratory parameters. Results We studied 41 patients [21 women; age 40.6 (10.8) years]. Neurological damage was parenchymal (n  = 33, 80.5%) and non-parenchymal (n  = 17, 41.5%). First BTs used were infliximab (n  = 19), adalimumab (n  = 14), golimumab (n  = 3), tocilizumab (n  = 3) and etanercept (n  = 2). After 6 months of BT, neurological remission was complete (n  = 23, 56.1%), partial (n  = 15, 37.6%) and no response (n  = 3, 7.3%). In addition, median (IQR) dose of oral prednisone decreased from 60 (30–60) mg/day at the initial visit to 5 (3.8–10) mg/day after 6 months (P  < 0.001). It was also the case for mean erythrocyte sedimentation rate [31.5 (25.6)–15.3 (11.9) mm/1st h, P  = 0.011] and median (IQR) C-reactive protein [1.4 (0.2–12.8) to 0.3 (0.1–3) mg/dl, P  = 0.001]. After a mean follow-up of 57.5 months, partial or complete neurological remission persisted in 37 patients (90.2%). BT was switched in 22 cases (53.6%) due to inefficacy (n  = 16) or adverse events (AEs) (n  = 6) and discontinued due to complete prolonged remission (n  = 3) or severe AE (n  = 1). Serious AEs were observed in two patients under infliximab treatment. Conclusions BT appears to be effective and relatively safe in refractory NBD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results